Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-500 with or without pembrolizumab in advanced solid tumors
NCT05070247Phase 2Terminated
- Sponsor
- Takeda
- Start
- Apr 2022
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-505 in pancreatic cancer (PC), hepatocellular carcinoma (HCC), mesothelioma, breast cancer, gastric cancer (GC), sponsored by Takeda. Started Apr 2022; status: terminated.
02
Drugs
TAK-505
03
Conditions
pancreatic cancer (PC)hepatocellular carcinoma (HCC)mesotheliomabreast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT05070247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05070247.